Evidence map›Paper›PMID 28398740›Full record

ArticleJournal of natural products2017

Structural Reassignment and Absolute Stereochemistry of Madurastatin C1 (MBJ-0034) and the Related Aziridine Siderophores: Madurastatins A1, B1, and MBJ-0035.

Andrew R Tyler, Hamed Mosaei, Stephanie Morton, Paul G Waddell, Corinne Wills, William McFarlane, Joe Gray, Michael Goodfellow, Jeff Errington, Nick Allenby and 2 more

Abstract read
In one paragraph

Article in Journal of natural products, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Andrew R Tyler
Hamed Mosaei
Stephanie Morton
Paul G Waddell
Corinne Wills
William McFarlane
Joe Gray
Michael Goodfellow
Jeff ErringtonDemuris Limited, Newcastle Biomedicine Bio-Incubators , Framlington Place, Newcastle upon Tyne, NE2 4HH, U.K.ORCID 0000-0002-6977-9388
Nick AllenbyDemuris Limited, Newcastle Biomedicine Bio-Incubators , Framlington Place, Newcastle upon Tyne, NE2 4HH, U.K.
Nikolay Zenkin

Funding

Wellcome Trust 102851
6 · The paper itself

Abstract

The madurastatins are pentapeptide siderophores originally described as containing an unusual salicylate-capped N-terminal aziridine ring. Isolation of madurastatin C1 (1) (also designated MBJ-0034), from Actinomadura sp. DEM31376 (itself isolated from a deep sea sediment), prompted structural reevaluation of the madurastatin siderophores, in line with the recent work of Thorson and Shaaban. NMR spectroscopy in combination with partial synthesis allowed confirmation of the structure of madurastatin C1 (1) as containing an N-terminal 2-(2-hydroxyphenyl)oxazoline in place of the originally postulated aziridine, while absolute stereochemistry was determined via Harada's advanced Marfey's method. Therefore, this work further supports Thorson and Shaaban's proposed structural revision of the madurastatin class of siderophores (madurastatins A1 (2), B1 (3), C1 (1), and MBJ-0036 (4)) as N-terminal 2-(2-hydroxyphenyl)oxazolines.

Indexed as

AziridinesMagnetic Resonance SpectroscopyMolecular StructureOligopeptidesPeptidesPiperidonesSiderophoresStereoisomerismAziridinesmadurastatin A1madurastatin B1madurastatin C1MBJ-0034MBJ-0035OligopeptidesPeptidesPiperidonesSiderophores

Identifiers

PMID28398740
PMCPMC6544507

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.